Symbols / IMUX
IMUX Chart
About
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 109.51M |
| Enterprise Value | 73.71M | Income | -103.05M | Sales | — |
| Book/sh | 0.11 | Cash/sh | 0.29 | Dividend Yield | — |
| Payout | 0.00% | Employees | 90 | IPO | — |
| P/E | — | Forward P/E | -2.50 | PEG | — |
| P/S | — | P/B | 8.59 | P/C | — |
| EV/EBITDA | -0.70 | EV/Sales | — | Quick Ratio | 1.17 |
| Current Ratio | 1.31 | Debt/Eq | 7.54 | LT Debt/Eq | — |
| EPS (ttm) | -0.80 | EPS next Y | -0.36 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-26 | ROA | -125.08% |
| ROE | -3.98% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 120.28M |
| Shs Float | 111.63M | Short Float | 5.55% | Short Ratio | 4.24 |
| Short Interest | — | 52W High | 1.35 | 52W Low | 0.51 |
| Beta | 1.59 | Avg Volume | 2.86M | Volume | 1.58M |
| Target Price | $4.88 | Recom | Strong_buy | Prev Close | $0.90 |
| Price | $0.91 | Change | 1.35% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.88
Mean price target
2. Current target
$0.91
Latest analyst target
3. DCF / Fair value
$-7.42
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.91
Low
$3.00
High
$10.00
Mean
$4.88
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-13 | main | D. Boral Capital | Buy → Buy | $4 |
| 2026-02-09 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2026-01-07 | main | D. Boral Capital | Buy → Buy | $8 |
| 2025-11-14 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-11-13 | main | D. Boral Capital | Buy → Buy | $8 |
| 2025-09-29 | init | Chardan Capital | — → Buy | $3 |
| 2025-09-26 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-09-25 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-08-08 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-06-25 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-06-05 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-05-29 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-05-23 | reit | B. Riley Securities | Buy → Buy | $5 |
| 2025-05-01 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-04-30 | main | D. Boral Capital | Buy → Buy | $17 |
| 2025-04-16 | reit | B. Riley Securities | Buy → Buy | $6 |
| 2025-04-15 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-04-10 | main | D. Boral Capital | Buy → Buy | $17 |
| 2025-04-01 | main | D. Boral Capital | Buy → Buy | $17 |
| 2025-03-25 | init | William Blair | — → Outperform | — |
- Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Immunic (IMUX) and Harmony Biosciences Holdings (HRMY) - The Globe and Mail Wed, 25 Feb 2026 15
- Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company - PR Newswire Fri, 13 Feb 2026 08
- Immunic stock soars after $400 million private placement deal - Investing.com Fri, 13 Feb 2026 08
- Why Did IMUX Stock Surge 33% Pre-Market Today? - Stocktwits Fri, 13 Feb 2026 13
- New Analyst Forecast: $IMUX Given $8.0 Price Target - Quiver Quantitative hu, 13 Nov 2025 08
- Immunic announces private placement, CEO change (IMUX:NASDAQ) - Seeking Alpha Fri, 13 Feb 2026 08
- A Look At Immunic (IMUX) Valuation After Oversubscribed Funding And Leadership Changes - Yahoo Finance Mon, 16 Feb 2026 08
- Immunic Stock Jumps After Pricing $400 Million Private Placement - Sahm Fri, 13 Feb 2026 08
- Why Is Immunic Stock (IMUX) Up 27% Today? - TipRanks Fri, 13 Feb 2026 08
- IMUX Stock Rises on Strong Market Sentiment: A Financial Analysis - timothysykes.com Fri, 13 Feb 2026 14
- Immunic shares gain on $400M raise to fund late-stage MS trials, commercial push - Proactive financial news Fri, 13 Feb 2026 09
- Immunic Announces Closing of Oversubscribed Private Placement Financing - PR Newswire ue, 17 Feb 2026 21
- A Look At Immunic (IMUX) Valuation After CEO Transition MS Data And US$200m Financing - simplywall.st Sat, 14 Feb 2026 08
- $IMUX stock is up 9% today. Here's what we see in our data. - Quiver Quantitative hu, 14 Aug 2025 07
- Positive Signs As Multiple Insiders Buy Immunic Stock - Yahoo Finance hu, 02 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 20000 | 16694 | — | Purchase at price 0.83 per share. | NASH DUANE D | Officer and Director | — | 2025-06-13 00:00:00 | D |
| 1 | 100000 | 76700 | — | Purchase at price 0.76 - 0.77 per share. | NEERMANN JOERG | Director | — | 2025-06-05 00:00:00 | D |
| 2 | 12512 | 9884 | — | Purchase at price 0.79 per share. | TARDIO JASON | President | — | 2025-06-05 00:00:00 | D |
| 3 | 12512 | 9884 | — | Purchase at price 0.79 per share. | TARDIO JASON | President | — | 2025-06-05 00:00:00 | D |
| 4 | 15000 | 11550 | — | Purchase at price 0.77 per share. | VITT DANIEL | Chief Executive Officer | — | 2025-06-04 00:00:00 | D |
| 5 | 15000 | 11550 | — | Purchase at price 0.77 per share. | VITT DANIEL | Officer and Director | — | 2025-06-04 00:00:00 | D |
| 6 | 45000 | 32076 | — | Purchase at price 0.71 per share. | WHALEY GLENN | Chief Financial Officer | — | 2025-06-03 00:00:00 | D |
| 7 | 143075 | 100024 | — | Purchase at price 0.70 per share. | RUDICK RICHARD ALAN | Director | — | 2025-06-03 00:00:00 | D |
| 8 | 25000 | 14000 | — | Stock Award(Grant) at price 0.56 per share. | WHALEY GLENN | Chief Financial Officer | — | 2025-05-30 00:00:00 | D |
| 9 | 87300 | 100369 | — | Purchase at price 1.15 per share. | RUDICK RICHARD ALAN | Director | — | 2024-11-12 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -97.92M | -99.11M | -53.47M | -91.58M |
| TotalUnusualItems | -4.80M | 0.00 | -32.97M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -4.80M | 0.00 | -32.97M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -100.51M | -93.61M | -120.41M | -92.94M |
| ReconciledDepreciation | 134.00K | 111.00K | 77.00K | 85.00K |
| EBITDA | -97.92M | -99.11M | -86.44M | -91.58M |
| EBIT | -98.05M | -99.22M | -86.52M | -91.67M |
| NetInterestIncome | 3.39M | 3.08M | 1.04M | 66.00K |
| InterestIncome | 3.39M | 3.08M | 1.04M | 66.00K |
| NormalizedIncome | -100.51M | -93.61M | -87.44M | -92.94M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -100.51M | -93.61M | -120.41M | -92.94M |
| TotalExpenses | 98.05M | 99.22M | 86.52M | 91.67M |
| TotalOperatingIncomeAsReported | -98.05M | -99.22M | -119.49M | -91.67M |
| DilutedAverageShares | 100.17M | 44.32M | 31.82M | 23.65M |
| BasicAverageShares | 100.17M | 44.32M | 31.82M | 23.65M |
| DilutedEPS | -1.00 | -2.11 | -3.78 | -3.93 |
| BasicEPS | -1.00 | -2.11 | -3.78 | -3.93 |
| DilutedNIAvailtoComStockholders | -100.51M | -93.61M | -120.41M | -92.94M |
| NetIncomeCommonStockholders | -100.51M | -93.61M | -120.41M | -92.94M |
| NetIncome | -100.51M | -93.61M | -120.41M | -92.94M |
| NetIncomeIncludingNoncontrollingInterests | -100.51M | -93.61M | -120.41M | -92.94M |
| NetIncomeContinuousOperations | -100.51M | -93.61M | -120.41M | -92.94M |
| PretaxIncome | -100.51M | -93.61M | -120.41M | -92.94M |
| OtherIncomeExpense | -5.84M | 2.54M | -34.93M | -1.35M |
| OtherNonOperatingIncomeExpenses | -5.84M | 2.54M | -1.96M | -1.35M |
| SpecialIncomeCharges | 0.00 | -32.97M | 0.00 | |
| ImpairmentOfCapitalAssets | 0.00 | 32.97M | 0.00 | |
| GainOnSaleOfSecurity | -4.80M | |||
| NetNonOperatingInterestIncomeExpense | 3.39M | 3.08M | 1.04M | 66.00K |
| InterestIncomeNonOperating | 3.39M | 3.08M | 1.04M | 66.00K |
| OperatingIncome | -98.05M | -99.22M | -86.52M | -91.67M |
| OperatingExpense | 98.05M | 99.22M | 86.52M | 91.67M |
| OtherOperatingExpenses | 17.25M | |||
| ResearchAndDevelopment | 80.05M | 83.22M | 71.25M | 61.12M |
| SellingGeneralAndAdministration | 18.01M | 16.01M | 15.26M | 13.30M |
| GeneralAndAdministrativeExpense | 18.01M | 16.01M | 15.26M | 13.30M |
| OtherGandA | 18.01M | 16.01M | 15.26M | 13.30M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 90.15M | 45.18M | 39.31M | 26.34M |
| ShareIssued | 90.15M | 45.18M | 39.31M | 26.34M |
| TotalDebt | 1.00M | 1.33M | 1.56M | 992.00K |
| TangibleBookValue | 18.43M | 28.93M | 113.68M | 94.14M |
| InvestedCapital | 18.43M | 28.93M | 113.68M | 127.11M |
| WorkingCapital | 17.16M | 27.80M | 112.79M | 93.59M |
| NetTangibleAssets | 18.43M | 28.93M | 113.68M | 94.14M |
| CapitalLeaseObligations | 1.00M | 1.33M | 1.56M | 992.00K |
| CommonStockEquity | 18.43M | 28.93M | 113.68M | 127.11M |
| TotalCapitalization | 18.43M | 28.93M | 113.68M | 127.11M |
| TotalEquityGrossMinorityInterest | 18.43M | 28.93M | 113.68M | 127.11M |
| StockholdersEquity | 18.43M | 28.93M | 113.68M | 127.11M |
| GainsLossesNotAffectingRetainedEarnings | 4.21M | 3.76M | 3.04M | -252.00K |
| OtherEquityAdjustments | 4.21M | 3.76M | 3.04M | -252.00K |
| RetainedEarnings | -511.40M | -410.89M | -317.28M | -196.87M |
| AdditionalPaidInCapital | 525.61M | 436.06M | 427.93M | 324.24M |
| CapitalStock | 8.00K | 4.00K | 4.00K | 3.00K |
| CommonStock | 8.00K | 4.00K | 4.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 22.44M | 25.37M | 14.07M | 11.98M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 264.00K | 639.00K | 992.00K | 584.00K |
| LongTermDebtAndCapitalLeaseObligation | 264.00K | 639.00K | 992.00K | 584.00K |
| LongTermCapitalLeaseObligation | 264.00K | 639.00K | 992.00K | 584.00K |
| CurrentLiabilities | 22.18M | 24.73M | 13.08M | 11.40M |
| OtherCurrentLiabilities | 676.00K | 271.00K | 239.00K | 177.00K |
| CurrentDebtAndCapitalLeaseObligation | 740.00K | 695.00K | 571.00K | 408.00K |
| CurrentCapitalLeaseObligation | 740.00K | 695.00K | 571.00K | 408.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 354.00K | 1.46M | 890.00K | 674.00K |
| PayablesAndAccruedExpenses | 20.41M | 22.30M | 11.38M | 10.14M |
| CurrentAccruedExpenses | 12.56M | 17.20M | 7.10M | 6.40M |
| Payables | 7.85M | 5.10M | 4.28M | 3.75M |
| OtherPayable | 285.00K | 373.00K | 532.00K | 246.00K |
| AccountsPayable | 7.56M | 4.73M | 3.75M | 3.50M |
| TotalAssets | 40.87M | 54.30M | 127.75M | 139.10M |
| TotalNonCurrentAssets | 1.54M | 1.76M | 1.89M | 34.11M |
| OtherNonCurrentAssets | 43.00K | 42.00K | ||
| GoodwillAndOtherIntangibleAssets | 0.00 | 32.97M | ||
| Goodwill | 0.00 | 32.97M | ||
| NetPPE | 1.54M | 1.76M | 1.85M | 1.10M |
| GrossPPE | 1.54M | 1.76M | 1.85M | 1.10M |
| OtherProperties | 1.54M | 1.76M | 1.85M | 1.10M |
| CurrentAssets | 39.33M | 52.53M | 125.86M | 104.99M |
| OtherCurrentAssets | 1.11M | 2.17M | 1.23M | 1.12M |
| PrepaidAssets | 1.87M | 2.31M | 5.61M | 14.85M |
| Receivables | 684.00K | 1.37M | 2.66M | 2.15M |
| TaxesReceivable | 684.00K | 1.37M | 2.66M | 2.15M |
| CashCashEquivalentsAndShortTermInvestments | 35.67M | 46.67M | 116.37M | 86.86M |
| OtherShortTermInvestments | 0.00 | 9.63M | 0.00 | |
| CashAndCashEquivalents | 35.67M | 46.67M | 106.75M | 86.86M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -85.03M | -71.16M | -65.26M | -83.30M |
| IssuanceOfCapitalStock | 191.00K | 853.00K | 95.57M | 42.75M |
| CapitalExpenditure | -264.00K | -334.00K | -112.00K | -67.00K |
| EndCashPosition | 35.67M | 46.67M | 106.75M | 86.86M |
| BeginningCashPosition | 46.67M | 106.75M | 86.86M | 127.45M |
| EffectOfExchangeRateChanges | -517.00K | 262.00K | -993.00K | -130.00K |
| ChangesInCash | -10.49M | -60.33M | 20.88M | -40.46M |
| FinancingCashFlow | 74.54M | 1.03M | 95.76M | 42.84M |
| CashFlowFromContinuingFinancingActivities | 74.54M | 1.03M | 95.76M | 42.84M |
| NetOtherFinancingCharges | 74.27M | |||
| ProceedsFromStockOptionExercised | 77.00K | 180.00K | 187.00K | 92.00K |
| NetPreferredStockIssuance | 0.00 | 55.99M | ||
| PreferredStockIssuance | 0.00 | 55.99M | ||
| NetCommonStockIssuance | 191.00K | 853.00K | 39.58M | 42.75M |
| CommonStockIssuance | 191.00K | 853.00K | 39.58M | 42.75M |
| InvestingCashFlow | -264.00K | 9.46M | -9.74M | -67.00K |
| CashFlowFromContinuingInvestingActivities | -264.00K | 9.46M | -9.74M | -67.00K |
| NetInvestmentPurchaseAndSale | 0.00 | 9.80M | -9.63M | 0.00 |
| SaleOfInvestment | 0.00 | 9.80M | ||
| PurchaseOfInvestment | -9.63M | 0.00 | ||
| NetPPEPurchaseAndSale | -264.00K | -334.00K | -112.00K | -67.00K |
| PurchaseOfPPE | -264.00K | -334.00K | -112.00K | -67.00K |
| OperatingCashFlow | -84.77M | -70.83M | -65.14M | -83.23M |
| CashFlowFromContinuingOperatingActivities | -84.77M | -70.83M | -65.14M | -83.23M |
| ChangeInWorkingCapital | 564.00K | 15.05M | 9.53M | -9.28M |
| ChangeInOtherCurrentLiabilities | 416.00K | 96.00K | -124.00K | 170.00K |
| ChangeInOtherCurrentAssets | 1.86M | 3.86M | ||
| ChangeInPayablesAndAccruedExpense | -1.72M | 11.09M | 2.16M | 3.35M |
| ChangeInAccruedExpense | -4.86M | 10.28M | 1.36M | 3.17M |
| ChangeInPayable | 3.15M | 817.00K | 799.00K | 176.00K |
| ChangeInAccountPayable | 3.15M | 817.00K | 799.00K | 176.00K |
| ChangeInPrepaidAssets | 3.86M | 7.49M | -12.80M | |
| OtherNonCashItems | 6.49M | 8.62M | ||
| StockBasedCompensation | 8.53M | 7.10M | 7.93M | 5.95M |
| AssetImpairmentCharge | 0.00 | 32.97M | 0.00 | |
| DepreciationAmortizationDepletion | 134.00K | 111.00K | 77.00K | 85.00K |
| DepreciationAndAmortization | 134.00K | 111.00K | 77.00K | 85.00K |
| OperatingGainsLosses | 30.00K | 523.00K | 4.76M | 4.33M |
| NetForeignCurrencyExchangeGainLoss | 30.00K | 523.00K | 4.76M | 4.33M |
| NetIncomeFromContinuingOperations | -100.51M | -93.61M | -120.41M | -92.94M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IMUX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|